SIH - A novel lipophilic iron chelator - Protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death

Journal of Molecular and Cellular Cardiology

Volumn 39, Issue 2, 2005, Pages 345-354

  Šimůnek, Tomáš ^a   Boer, Christa ^b   Bouwman, R Arthur ^b   Vlasblom, Ronald ^b   Versteilen, Amanda M G ^b   Štěrba, Martin ^c   Geršl, Vladimír ^c   Hrdina, Radomír ^a   Poňka, Přemysl ^d   De Lange, Jaap J ^b   Paulus, Walter J ^b   Musters, René J P ^b  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CHARLES UNIVERSITY   (Czech Republic)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Cardioprotection; Deferoxamin (DFO); Iron chelation; Oxidative stress; Salicylaldehyde isonicotinoyl hydrazone (SIH)

Indexed keywords

DEFEROXAMINE; HYDROGEN PEROXIDE; IRON CHELATING AGENT; LIPOCORTIN 5; PROPIDIUM IODIDE; SALICYLALDEHYDE ISONICOTINOYL HYDRAZONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL DEATH; CELL PROTECTION; CELL STRUCTURE; CHROMATIN; CLINICAL PRACTICE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; HEART MUSCLE INJURY; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; NICK END LABELING; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; STAINING;

ALDEHYDES; ANIMALS; CELL DEATH; CELL LINE; CELL SHAPE; CELL SURVIVAL; CYTOPROTECTION; HYDRAZONES; HYDROGEN PEROXIDE; IRON CHELATING AGENTS; MEMBRANE POTENTIALS; MITOCHONDRIA; MYOBLASTS, CARDIAC; OXIDATIVE STRESS; RATS;

EID: 22244446427     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2005.05.008     Document Type: Article

References (46)

1. D.K. Das, and N. Maulik Preconditioning potentiates redox signaling and converts death signal into survival signal Arch. Biochem. Biophys. 420 2003 305 311
2. O. Oldenburg, M.V. Cohen, D.M. Yellon, and J.M. Downey Mitochondrial K(ATP) channels: role in cardioprotection Cardiovasc. Res. 55 2002 429 437
3. X.L. Tang, H. Takano, A. Rizvi, J.F. Turrens, Y. Qiu, and W.J. Wu Oxidant species trigger late preconditioning against myocardial stunning in conscious rabbits Am. J. Physiol. Heart Circ. Physiol. 282 2002 H281 H291
4. B. Halliwell, and J.M. Gutteridge Free radicals in biology and medicine. 3rd ed 1999 Oxford University Press New York
5. R. Bolli, M. Zughaib, X.Y. Li, X.L. Tang, J.Z. Sun, and J.F. Triana Recurrent ischemia in the canine heart causes recurrent bursts of radical production that have a cumulative effect on contractile function. A pathophysiological basis for chronic myocardial "stunning" J. Clin. Invest. 96 1995 1066 1084
6. R. Ferrari, L. Agnoletti, L. Comini, G. Gaia, T. Bachetti, A. Cargnoni, C. Ceconi, S. Curello, and O. Visioli Oxidative stress during myocardial ischaemia and heart failure Eur. Heart J. 19 1998 2 11
7. H. Tsutsui Oxidative stress in heart failure: the role of mitochondria Intern. Med. 40 2001 1177 1182
8. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol. Rev. 56 2004 185 229
9. J.P. Kehrer The Haber-Weiss reaction and mechanisms of toxicity Toxicology 149 2000 43 50
10. S.I. Liochev The mechanism of "Fenton-like" reactions and their importance for biological systems. A biologist's view Met. Ions Biol. Syst. 36 1999 1 39
11. D.W. Reif Ferritin as a source of iron for oxidative damage Free Radic. Biol. Med. 12 1992 417 427
12. M. Chevion, Y. Jiang, R. Har-El, E. Berenshtein, G. Uretzky, and N. Kitrossky Copper and iron are mobilized following myocardial ischemia: possible predictive criteria for tissue injury Proc. Natl. Acad. Sci. USA 90 1993 1102 1106
13. B. Halliwell Protection against tissue damage in vivo by desferrioxamine: what is its mechanism of action? Free Radic. Biol. Med. 7 1989 645 651
14. C. Hershko Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators Baillieres Clin. Haematol. 7 1994 965 1000
15. T.B. Chaston, and D.R. Richardson Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity Am. J. Hematol. 73 2003 200 210
16. E.E. Voest, G. Vreugdenhil, and J.J.M. Marx Iron-chelating agents in non-iron overload conditions Ann. Intern. Med. 120 1994 490 499
17. P. Dobsak, J. Siegelova, J.E. Wolf, L. Rochette, J.C. Eicher, and J. Vasku Prevention of apoptosis by deferoxamine during 4:h of cold cardioplegia and reperfusion: in vitro study of isolated working rat heart model Pathophysiology 9 2002 27 32
18. V. Gabutti, and A. Piga Results of long-term iron-chelating therapy Acta Haematol. 95 1996 26 36
19. J.L. Buss, M. Hermes-Lima, and P. Ponka Pyridoxal isonicotinoyl hydrazone and its analogues Adv. Exp. Med. Biol. 509 2002 205 229
20. G. Zanninelli, H. Glickstein, W. Breuer, P. Milgram, P. Brissot, and R.C. Hider Chelation and mobilization of cellular iron by different classes of chelators Mol. Pharmacol. 51 1997 842 852
21. S. Epsztejn, O. Kakhlon, H. Glickstein, W. Breuer, and I. Cabantchik Fluorescence analysis of the labile iron pool of mammalian cells Anal. Biochem. 248 1997 31 40
22. M. Hermes-Lima, N.C. Santos, J. Yan, M. Andrews, H.M. Schulman, and P. Ponka EPR spin trapping and 2-deoxyribose degradation studies of the effect of pyridoxal isonicotinoyl hydrazone (PIH) on •OH formation by the Fenton reaction Biochim. Biophys. Acta 1426 1999 475 482
23. M. Akao, B. O'Rourke, Y. Teshima, J. Seharaseyon, and E. Marban Mechanistically distinct steps in the mitochondrial death pathway triggered by oxidative stress in cardiac myocytes Circ. Res. 92 2003 186 194
24. H.W. Chen, C.T. Chien, S.L. Yu, Y.T. Lee, and W.J. Chen Cyclosporine A regulates oxidative stress-induced apoptosis in cardiomyocytes: mechanisms via ROS generation, iNOS and Hsp70 Br. J. Pharmacol. 137 2002 771 781
25. G. Dodoni, A. Alexandre, and F. Di Lisa Formation of reactive oxygen species (ROS), mitochondrial dysfunction and cell death in H9c2 cardiomyoblasts J. Mol. Cell. Cardiol. 36 2004 724 725 (Abstract)
26. A. Clerk, S.M. Cole, T.E. Cullingford, J.G. Harrison, M. Jormakka, and D.M. Valks Regulation of cardiac myocyte cell death Pharmacol. Ther. 97 2003 223 261
27. K.M. Regula, K. Ens, and L.A. Kirshenbaum Mitochondria-assisted cell suicide: a license to kill J. Mol. Cell. Cardiol. 35 2003 559 567
28. J.T. Edward, M. Gauthier, F.L. Chubb, and P. Ponka Synthesis of new acylhydrazones as iron-chelating compounds J. Chem. Eng. Data 33 1988 538 540
29. F. Haber, and J. Weiss The catalytic decomposition of hydrogen peroxide by iron salts Proc. R. Soc. London Ser. A 147 1934 332 351
30. J.C. Kwok, and D.R. Richardson The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity Redox Rep. 5 2000 317 324
31. R. Bolli, B.S. Patel, W.X. Zhu, P.G. O'Neill, C.J. Hartley, and M.L. Charlat The iron chelator desferrioxamine attenuates postischemic ventricular dysfunction Am. J. Physiol. 253 1987 H1372 H1380
32. K. Chopra, M. Singh, N. Kaul, K.I. Andrabi, and N.K. Ganguly Decrease of myocardial infarct size with desferrioxamine: possible role of oxygen free radicals in its ameliorative effect Mol. Cell. Biochem. 113 1992 71 76
33. S. Sweetman Martindale: the complete drug reference. 33rd ed 2002 Pharmaceutical Press London
34. M.R. Summers, A. Jacobs, D. Tudway, P. Perera, and C. Ricketts Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects Br. J. Haematol. 42 1979 547 555
35. J.B. Lloyd, H. Cable, and C. Rice-Evans Evidence that desferrioxamine cannot enter cells by passive diffusion Biochem. Pharmacol. 41 1991 1361 1363
36. H. Cable, and J.B. Lloyd Cellular uptake and release of two contrasting iron chelators J. Pharm. Pharmacol. 51 1999 131 134
37. A. Beresewicz, and M. Horackova Alterations in electrical and contractile behavior of isolated cardiomyocytes by hydrogen peroxide: possible ionic mechanisms J. Mol. Cell. Cardiol. 23 1991 899 918
38. M. Horackova, P. Ponka, and Z. Byczko The antioxidant effects of a novel iron chelator salicylaldehyde isonicotinoyl hydrazone in the prevention of H(2)O(2) injury in adult cardiomyocytes Cardiovasc. Res. 47 2000 529 536
39. L. Gille, and H. Nohl Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity Free Radic. Biol. Med. 23 1997 775 782
40. L.R. Wiseman, and C.M. Spencer Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy Drugs 56 1998 385 403
41. B.B. Hasinoff, K. Hellmann, E.H. Herman, and V.J. Ferrans Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines Curr. Med. Chem. 5 1998 1 28
42. A. Dendorfer, M. Heidbreder, T. Hellwig-Burgel, O. Johren, F. Qadri, and P. Dominiak Deferoxamine induces prolonged cardiac preconditioning via accumulation of oxygen radicals Free Radic. Biol. Med. 38 2005 117 124
43. G. Wright, J.J. Higgin, R.T. Raines, C. Steenbergen, and E. Murphy Activation of the prolyl hydroxylase oxygen-sensor results in induction of GLUT1, heme oxygenase-1, and nitric-oxide synthase proteins and confers protection from metabolic inhibition to cardiomyocytes J. Biol. Chem. 278 2003 20235 20239
44. M. Creighton-Gutteridge, and R.M. Tyrrell A novel iron chelator that does not induce HIF-1 activity Free Radic. Biol. Med. 33 2002 356 363
45. D.B. Zorov, C.R. Filburn, L.O. Klotz, J.L. Zweier, and S.J. Sollott Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes J. Exp. Med. 192 2000 1001 1014
46. A.L. Nieminen Apoptosis and necrosis in health and disease: role of mitochondria Int. Rev. Cytol. 224 2003 29 55